Montelukast-loaded nanostructured lipid carriers: Part i Oral bioavailability improvement

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 88, Issue 1, 2014, Pages 160-168

  Patil Gadhe, Arpana ^a   Pokharkar, Varsha ^a  

^a BHARATI VIDYAPEETH DEEMED UNIVERSITY   (India)

Author keywords

Asthma; Cationic surfactant; Montelukast; Nanostructured lipid carrier; Precirol ATO5; Systemic bioavailability

Indexed keywords

ACETIC ACID DERIVATIVE; DRUG CARRIER; LIPID; MONTELUKAST; NANOMATERIAL; NANOPARTICLE; QUINOLINE DERIVATIVE; SURFACTANT;

ANIMAL; AREA UNDER THE CURVE; ASTHMA; CHEMISTRY; DIFFERENTIAL SCANNING CALORIMETRY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INFRARED SPECTROSCOPY; MALE; PARTICLE SIZE; RAT; SOLUBILITY; TRANSMISSION ELECTRON MICROSCOPY; WISTAR RAT; X RAY DIFFRACTION;

ACETATES; ANIMALS; AREA UNDER CURVE; ASTHMA; CALORIMETRY, DIFFERENTIAL SCANNING; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG CARRIERS; LIPIDS; MALE; MICROSCOPY, ELECTRON, TRANSMISSION; NANOPARTICLES; NANOSTRUCTURES; PARTICLE SIZE; QUINOLINES; RATS; RATS, WISTAR; SOLUBILITY; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; SURFACE-ACTIVE AGENTS; X-RAY DIFFRACTION;

EID: 84934289523     PISSN: 09396411     EISSN: 18733441     Source Type: Journal    
DOI: 10.1016/j.ejpb.2014.05.019     Document Type: Article

References (50)

1. K.M. Gross, and C.D. Ponte New strategies in the medical management of asthma Am. Fam. Phys. 58 1998 89 100
2. https://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails (accessed 12.03.14).
3. R. Ramakrishnan, E. Migoya, and B. Knorr A population pharmacokinetic model for montelukast disposition in adults and children Pharm. Res. 22 2005 532 540
4. E. Migoya, G.L. Kearns, A. Hartford, J. Zhao, J.V. Adelsberg, C.A. Tozzi, B. Knorr, and P. Deutsch Pharmacokinetics of montelukast in asthmatic patients 6 and 24 months old J. Clin. Pharmacol. 44 2004 487 494
5. W. Storms Update on montelukast and its role in the treatment of asthma, allergic rhinitis and exercise-induced bronchoconstriction Expert. Opin. Pharmacother 8 2007 2173 2187
6. F.M. de Benedictis, S. Vaccher, and D. de Benedictis Montelukast sodium for exercise-induced asthma Drugs Today (Barc) 44 2008 845 855
7. A. Nayak, and R.B. Langdon Montelukast in the treatment of allergic rhinitis: an evidence-based review Drugs 67 2007 887 901
8. A. Harugeri, G. Parthasarathi, J. Sharma, G.A. D'Souza, and M. Ramesh Montelukast induced acute hepatocellular liver injury J. Postgrad. Med. 55 2009 141 142
9. H. Shete, and V. Patravale Long chain lipid based tamoxifen NLC. Part I: Preformulation studies, formulation development and physicochemical characterization Int. J. Pharm. 454 2013 573 583
10. R.J. Dockhorn, R.A. Baumgartner, J.A. Leff, M. Noonan, K. Vandormael, W. Stricker, D.E. Weinland, and T.F. Reiss Comparison of the effects of intravenous and oral montelukast on airway function: a double blind, placebo controlled, three period, crossover study in asthmatic patients Thorax 55 2000 260 265
11. K.G.B. Kumar, and E. Mahesh Formulation and evaluation of montelukast sodium fast dissolving tablets Asian J. Biomed. Pharm. Sci. 2 2012 75 82
12. A. Patil, T. Aman, N. Bhargava, P. Abhilash, M. Turaga, and S. Kulkarni Formulation and evaluation of mouth dissolving tablets of montelukast sodium Res. J. Pharm. Bio. Chem. Sci. 2 2011 268 274
13. Priyanka, and P.B. Kumar Formulation development and evaluation of montelukast sodium chewable tablets J. Chem. Pharm. Sci. 6 2013 35 40
14. Nerella, P. Dontha, A. Uppuluru, and S.K. Konda Formulation and evaluation of in situ mucoadhesive nasal gel of montelukast sodium Der Pharm. Sinica 5 2014 1 8
15. A.N. Zaid, S. Natour, A. Qaddomi, and A.A. Ghoush Formulation and in vitro and in vivo evaluation of film-coated montelukast sodium tablets using Opadry® yellow 20A82938 on an industrial scale Drug Des. Devel. Ther. 7 2013 83 91
16. G. Krishnaveni, M. Muthukumaran, and B. Krishnamoorthy Development and evaluation of pulsatile drug delivery system containing montelukast sodium by press coated tablet using natural polysaccharides Int. J. Adv. Pharm. Gen. Res. 1 2013 41 51
17. B.U. Janugade, S.S. Patil, S.V. Patil, and P.D. Lade Formulation and evaluation of press-coated montelukast sodium tablets for pulsatile drug delivery system Int. J. ChemTech Res. 1 2009 690
18. O.P. Ranjan, U.Y. Nayak, M.S. Reddy, S.J. Dengale, P.B. Musmade, and N. Udupa Osmotically controlled pulsatile release capsule of montelukast sodium for chronotherapy: Statistical optimization, in vitro and in vivo evaluation Drug Deliv. 2013 10.3109/10717544.2013.853209
19. P. Bailpattar, P. Karwa, K. Patel, M.Md. Sahidullah, and P.M. Irshad Formulation and evaluation of time controlled drug delivery system of montelukast sodium Int. J. Pharm. Inno. 2 2012 1 12
20. A. Patil-Gadhe, and V. Pokharkar Single step spray drying method to develop proliposomes for inhalation: a systematic study based on quality by design approach Pulm. Pharmacol. Ther. 27 2014 197 207
21. R. Pandey, and G.K. Khuller Solid lipid particle-based inhalable sustained drug delivery system against experimental tuberculosis Tuberculosis (Edinb) 85 2005 227 234
22. S. Weber, A. Zimmer, and J. Pardeike Solid Lipid Nanoparticles (SLN) and Nanostructured Lipid Carriers (NLC) for pulmonary application: a review of the state of the art Eur. J. Pharm. Biopharm. 86 2014 7 22
23. C.Y. Zhuang, N. Li, M. Wang, X.N. Zhang, W.S. Pan, J.J. Peng, Y.S. Pan, and X. Tang Preparation and characterization of vinpocetine loaded nanostructured lipid carriers (NLC) for improved oral bioavailability Int. J. Pharm. 394 2010 179 185
24. C.M. O'Driscoll, and B.T. Griffin Biopharmaceutical challenges associated with drugs with low aqueous solubility - the potential impact of lipid-based formulations Adv. Drug Deliv. Rev. 60 2008 617 624
25. R.H. Müller, M. Radtke, and S.A. Wissing Solid nanoparticle (SLN) and nanostructured lipid carrier (NLC) in cosmetic and dermatological preparations Adv. Drug Deliv. Rev. 54 2002 131 155
26. S.M. Caliph, W.N. Charman, and C.J. Porter Effect of short-, medium-, and longchain fatty acid-based vehicles on the absolute oral bioavailability and intestinal lymphatic transport of halofantrine and assessment of mass balance in lymphcannulated and non-cannulated rats J. Pharm. Sci. 89 2000 1073 1084
27. C.J. Porter, and W.N. Charman Intestinal lymphatic drug transport: an update Adv. Drug Deliv. Rev. 50 2001 61 80
28. C.J. Porter, N.L. Trevaskis, and W.N. Charman Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs Nat. Rev. Drug Discov. 6 2007 231 248
29. M. Zheng, M. Falkeborg, Y. Zheng, T. Yang, and X. Xu Formulation and characterization of nanostructured lipid carriers containing a mixed lipids core Colloids Surf. A 430 2013 76 84
30. M.J. Tsai, P.C. Wu, Y.B. Huang, J.S. Chang, C.L. Lin, Y.H. Tsai, and J.Y. Fang Baicalein loaded in tocol nanostructured lipid carriers (tocol NLCs) for enhanced stability and brain targeting Int. J. Pharm. 423 2012 461 470
31. P.U. Singare, and J.D. Mhatre Cationic surfactants from arginine: synthesis and physicochemical properties Am. J. Chem. 2 2012 186 190
32. K. Priyanka, and A.A. Sathali Preparation and evaluation of montelukast sodium loaded solid lipid nanoparticles J. Young Pharm. 4 2012 129 137
33. R. Nair, K.S.A. Kumar, K.V. Priya, and M. Sevukarajan Recent advances in solid lipid nanoparticle based drug delivery J. Biomed. Sci. Res. 3 2011 368 384
34. K.N. Raju, T.G. Swamy, and A.L. Rao Development and validation of RP-HPLC method for the determination of montelukast sodium in bulk and in pharmaceutical formulation Int. J. Pharm. Chem. Biol. Sci. 1 2011 12 16
35. Y.F. Luo, D.W. Chen, L.X. Ren, X.L. Zhao, and J. Qin Solid lipid nanoparticles for enhancing vinpocetine's oral bioavailability J. Control. Rel. 114 2006 53 59
36. Z. Atcha, C. Rourke, A.H.P. Neo, C.W.H. Goh, J.S.K. Lim, C.C. Aw, E.R. Browne, and D.J. Pemberton Alternative method of oral dosing for rats J. Am. Assoc. Lab. Anim. Sci. 49 2010 335 343
37. R. Zhao, W.Z. Shi, Y.M. Zhang, S.H. Fang, and E.Q. Wei Montelukast, a cysteinyl leukotriene receptor-1 antagonist, attenuates chronic brain injury after focal cerebral ischaemia in mice and rats J. Pharm. Pharmacol. 63 2011 550 557
38. R.H. Müller, M. Radtke, and S.A. Wissing Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations Adv. Drug Deliv. Rev. 54 2002 S131 S155
39. R.M. Khalil, A.A. El-Bary, M.A. Kassem, M.M. Ghorab, M.B. Ahmed, Solid lipid nanoparticles for topical delivery of meloxicam: Development and in vitro characterization, in: 1st Annual International Interdisciplinary Conference, AIIC 2013, 24-26 April, Azores, Portugal - Proceedings, pp. 779-798.
40. A. Azeem, M. Rizwan, F.J. Ahmad, Z. Iqbal, R.K. Khar, M. Aqil, and S. Talegaonkar Nanoemulsion components screening and selection: a technical note AAPS PharmSciTech 10 2009 69 76
41. G.A. Morris, J. Castile, A. Smith, G.G. Adams, and S.E. Harding The effect of prolonged storage at different temperatures on the particle size distribution of tripoly-phosphate (TPP) - chitosan nanoparticles Carbohydr. Polym. 84 2011 1430 1434
42. M.N. Padamwar, and V.B. Pokharkar Development of vitamin loaded topical liposomal formulation using factorial design approach: drug deposition and stability Int. J. Pharm. 320 2006 37 44
43. S. Honary, and F. Zahir Effect of zeta potential on the properties of nano-drug delivery systems - a review Part 1 Trop. J. Pharm. Res. 12 2013 255 264
44. S. Honary, and F. Zahir Effect of zeta potential on the properties of nano-drug delivery systems - a review Part 2 Trop. J. Pharm. Res. 12 2013 265 273
45. D.D. Kumbhar, and V.B. Pokharkar Physicochemical investigations on an engineered lipid-polymerhybrid nanoparticle containing a model hydrophilic active, zidovudine Colloids Surf. A 436 2013 714 725
46. L. Montenegro, M.G. Sarpietro, S. Ottimo, G. Puglisi, and F. Castelli Differential scanning calorimetry studies on sunscreen loaded solid lipid nanoparticles prepared by the phase inversion temperature method Int. J. Pharm. 415 2011 301 306
47. D.G. Peroni, G.L. Piacentini, M. Ress, A. Bodini, A. Loiacono, R. Aralla, and A.L. Boner Time efficacy of a single dose of montelukast on exercise-induced asthma in children Pediatr. Allergy Immunol. 13 2002 434 437
48. P. Costa, and J.M.S. Lobo Modeling and comparison of dissolution profiles Eur. J. Pharm. Sci. 13 2001 123 133
49. http://www.merck.ca/assets/en/pdf/products/SINGULAIR-PM-E.pdf.
50. E.K. Ayman, and M. Varma Oral absorption, intestinal metabolism and human oral bioavailability J. Paxton, Topics on Drug Metabolism 2012 InTech Europe 1 34